Loading...
Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
Manasa, J Varghese, V Pond, SLK Rhee, SY Tzou, PL Fessel, WJ Jang, KS White, E Rögnvaldsson, T Katzenstein, DA
Manasa, J
Varghese, V
Pond, SLK
Rhee, SY
Tzou, PL
Fessel, WJ
Jang, KS
White, E
Rögnvaldsson, T
Katzenstein, DA
Citations
Altmetric:
Genre
Journal Article
Date
2017-12-01
Advisor
Committee member
Group
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
10.1038/s41598-017-11893-8
Abstract
© 2017 The Author(s). Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp41-CD) reduce protease inhibitor (PI) susceptibility without PI-resistance mutations in protease. However, no gag and gp41-CD mutations definitively responsible for reduced PI susceptibility have been identified in individuals with virological failure (VF) while receiving a boosted PI (PI/r)-containing regimen. To identify gag and gp41 mutations under selective PI pressure, we sequenced gag and/or gp41 in 61 individuals with VF on a PI/r (n = 40) or NNRTI (n = 20) containing regimen. We quantified nonsynonymous and synonymous changes in both genes and identified sites exhibiting signal for directional or diversifying selection. We also used published gag and gp41 polymorphism data to highlight mutations displaying a high selection index, defined as changing from a conserved to an uncommon amino acid. Many amino acid mutations developed in gag and in gp41-CD in both the PI-A nd NNRTI-treated groups. However, in neither gene, were there discernable differences between the two groups in overall numbers of mutations, mutations displaying evidence of diversifying or directional selection, or mutations with a high selection index. If gag and/or gp41 encode PI-resistance mutations, they may not be confined to consistent mutations at a few sites.
Description
Citation
Citation to related work
Springer Science and Business Media LLC
Has part
Scientific Reports
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu